Stent wars: Biodegradable drug eluting stents best bare metal in STEMI patients

Wed, 08/22/2012 - 3:11pm
Mass Device

Drug-eluting and bare metal stents duke it out in another clinical trial, with biodegradable DES cutting adverse events nearly in half for STEMI patients.

Drug-eluting biodegradable stents cut adverse events in half when compared with bare-metal stents in patients with ST-segment elevation myocardial infarction, according to a new study.

The study, dubbed the Comfortable AMI trial, reported 24 adverse cardiac events at 1 year of follow-up in STEMI patients treated with DES, compared with 49 events in patients treated with BMS, providing more fuel to the ongoing controversy over whether the more expensive DES devices are worth the price.


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.